The Value of Screening and Early Detection in Diabetic Retinopathy

Allen Dobson, Jr., MD, FAAFP; Wade Brosius, DO; and Shelton Hager, MD, provide an overview of diabetic retinopathy and discuss risk factors leading to its pathogenesis.

Wade Brosius, DO, and Steven Peskin, MD, discuss the clinical and economic burden of diabetic retinopathy, highlighting the impact on patients’ quality of life and the health care system.

An expert in the management of diabetes provides insight into common challenges leading to low rates of diabetic retinopathy screening in primary care settings, highlighting the need to increase access to care.

Key opinion leaders in diabetes management comment on the practical considerations of screening in clinical practices and note the importance of creating a replicable workflow for busy practices.

Allen Dobson, Jr., MD, FAAFP, reviews the case of a 67-year-old man with type 2 diabetes and the panel discusses initial diagnosis and management.

Key opinion leaders in diabetes management provide insight on recognizing and addressing barriers to care and screening for diabetic retinopathy.

Wade Brosius, DO, and Steven Peskin, MD, review the cost of care and reimbursement schemes available to practitioners completing diabetic retinopathy screenings.

Allen Dobson, Jr., MD, FAAFP, reviews the case of a 49-year-old woman with type 2 diabetes and the panel comments on their approaches to continued care and disease prevention.

A panel of experts in the management of diabetes answer questions relating to the importance of early screening and detection of diabetic retinopathy and provide practice pearls for how to facilitate in-office screenings.

Wade Brosius, DO, Shelton Hager, MD, and Steven Peskin, MD, answer questions relating to diabetic retinopathy screening devices and highlight novel technologies utilized in this space.